for Jan 17, 2023 through Jan 23, 2023
🔥APPIC study🔥
— Antibiotic Steward Bassam Ghanem🆔🌟 (@ABsteward) January 18, 2023
2 days of IV antibiotics for pts with complex appendicitis post laparoscopic appendicectomy is non-inferior to 5 days in terms of infectious complications & mortality within 90d, based on a non-inferiority margin of 7·5%#shorterisbetterhttps://t.co/f7YT7JkQav pic.twitter.com/okUscEfTDM
Pip-tazo plus vancomycin has been implicated in numerous studies as a cause of AKI. But is this in part a pseudo-association? Mechanism: Pip-tazo inhibits tubular secretion of creatinine -- analogous to DTG, BIC, cobi, and TMP/SMX. H/T @BWDionne https://t.co/lgAeMLe8Sv pic.twitter.com/koRn6Ef007
— Paul Sax (@PaulSaxMD) January 19, 2023
A warning in 2015 we ignored.
— Peter Collignon (@CollignonPeter) January 17, 2023
Can anyone give examples of any “gain of function” research that has given us any tangible benefits? I can’t see how it has helped with any better vaccines or drugs for flu, coronavirus etc
All risk and pain with no gain https://t.co/09SYM8Xigj
New meta-analysis: Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regressionhttps://t.co/flBzDDtcLK pic.twitter.com/ABNbu2smPM
— The Lancet Infectious Diseases (@TheLancetInfDis) January 19, 2023
🆕️⚡️⚡️Review article @JAMA_current
— Antibiotic Steward Bassam Ghanem🆔🌟 (@ABsteward) January 19, 2023
Management of Latent Tuberculosis Infection
🌟Proposed LTBI Treatment Algorithm for clinicians 🌟#IDTwitter https://t.co/tIuu3iJHF9 pic.twitter.com/ltkacMlw9H
🔥Wow🔥
— Antibiotic Steward Bassam Ghanem🆔🌟 (@ABsteward) January 21, 2023
Do we need to add anaerobic coverage in the treatment of
biliary tract infections (acute holecystitis & ascending cholangitis)?
🆕️⚡️⚡️Propensity score-matched cohort study @jac_amr
No statistically significant difference in mortality or relapse https://t.co/xYxcCFYl0i pic.twitter.com/g08B39SzkZ
Infectious diseases experts are warning that almost all available antiviral medications are increasingly ineffective against the “soup” of Omicron descendants now circulating in Australia.#COVID19Aus #antiviralmedications
— Denis - The COVID info guy - (@BigBadDenis) January 21, 2023
Source: https://t.co/V3wNYcssRM pic.twitter.com/JMAEosdSiS
Hey #IDTwitter, especially those out there doing clinical research: Excited that @CIDJournal now offers format free submissions.
— Paul Sax (@PaulSaxMD) January 23, 2023
Another big change coming soon -- stay tuned!https://t.co/N6h6ryGIy1 pic.twitter.com/FytEBJVBA1
Start tomorrow! 6th Annual Texas Medical Conference Conference on Antimicrobial Resistance & Stewardship in collaboration with @ARLGnetwork and T32 @EmoryUniversity and U Pittsburgh. Supported by @ASMicrobiology @asm_tmc @ErinMcCreary https://t.co/FyqwheJP0o
— Cesar Arias (@SuperBugDoc) January 17, 2023
🆕️⚡️Retrospective study
— Antibiotic Steward Bassam Ghanem🆔🌟 (@ABsteward) January 20, 2023
Outcomes of Daptomycin Plus Ceftaroline Vs Alternative in patients who underwent a change in antibiotic therapy for persistent MRSA bacteremia after initial treatment with vancomycin or Daptomycin
No difference #IDTwitter https://t.co/I6We7sZbou
🆕️⚡️⚡️ Excellent review about PJI @NEJM @micro_rp
— Antibiotic Steward Bassam Ghanem🆔🌟 (@ABsteward) January 19, 2023
🌟Periprosthetic Joint Infection🌟
Featuring : OVIVA DATIPO
Many exciting practice changing RCTs are ongoing ,stay tuned!@MayoClinicINFD #IDTwitter @TweetsOrtho #orthotwitterhttps://t.co/BUhbubxxNI pic.twitter.com/scnnix58fy
I like this study , it's on our list of the Best Infectious Diseases Articles From 2022 @IDstewardship
— Antibiotic Steward Bassam Ghanem🆔🌟 (@ABsteward) January 19, 2023
🌟Visual abstract 👇🌟 #IDTwitter https://t.co/JL07NLa3BV pic.twitter.com/o6xW4yeD5A
Acinetobacter baumannii kills fungi by injecting a DNase effector into cells via its T6SS—targeted degradation of the immunity protein preventing the effector from harming A. baumannii itself may be an effective strategy to kill the pathogen. @mbiojournal: https://t.co/YtcOG1r04D pic.twitter.com/xeNJvhcGnH
— ASM (@ASMicrobiology) January 20, 2023
Have you ever had the Stewardship Struggles? 🥴🥴
— SIDP (@SIDPharm) January 20, 2023
Drs. @ValerieVaughnMD, @JasonGNewland and @The_Real_LDA join @ErinMcCreary to talk through how to how to harness the power of data to move through common barriers in day-to-day #stewardship @biomerieux
🎧 https://t.co/XTxayI4EF8 pic.twitter.com/s2tKdzkYD0
Dual β-lactam therapy provides a promising option for persistent MSSA bacteraemia
— Antibiotic Steward Bassam Ghanem🆔🌟 (@ABsteward) January 18, 2023
ICYMI ⚡️case series @BBookstaver_USC et Al @jac_amr
Successful use of nafcillin & ceftaroline combination therapy for persistent MSSA bacteraemia and endocarditis #IDTwitter https://t.co/vbMAxKuhWR
Is penicillin allergy de-labelling about to find its place in UK antimicrobial stewardship strategy? https://t.co/wsm2mD0e2K
— Neil Powell (@neilthepcist) January 19, 2023
Fight against #AntimicrobialResistance doesn't only happen in #labs with development of new drugs.
— NIYIGENA Emmanuel (@NiyigenaE_) January 17, 2023
We also need to fight it, with better urban planning, waste disposal, wastewater treatment & #livestock husbandry practices.
Read more: https://t.co/Vt6dx1trm2 #RwOT#PL#AMR pic.twitter.com/41t8DJOT79
A 🆕️⚡️⚡️systematic review and meta-analysis
— Antibiotic Steward Bassam Ghanem🆔🌟 (@ABsteward) January 18, 2023
Comparing complication rates of midline catheter vs. peripherally inserted central catheter (PICC)
▶️Patients who use midline might experience fewer CRBSI than those who use PICC #IDTwitter https://t.co/A21BsXbHTq pic.twitter.com/UJYuHYtZa1
🔥Hot Topic🔥
— Antibiotic Steward Bassam Ghanem🆔🌟 (@ABsteward) January 20, 2023
The 1-hour 🕛💉
Sepsis & antibiotics: When should we deploy a parachute?
Damned if you do (administer antibiotics unnecessarily)
Damned if you don't (administer antibiotics “in time”
So what options does the clinician at the bedside have? https://t.co/4LvJkX9Yco
Our lab is recruiting! Large network of great PIs studying infectious diseases. Many different pathogens & infection sites. Cool technology. https://t.co/WvBzWG2QOb
— Ana Rita Brochado (@AnaRitaBrochad1) January 23, 2023
🆕️⚡️Retrospective single center study showed no difference in clinical failure rates in adult patients receiving PO-stepdown antibiotic therapy compared to full course IV therapy for uncomplicated Streptococcal bloodstream infection #IDTwitter https://t.co/GzRKerK5Mf
— Antibiotic Steward Bassam Ghanem🆔🌟 (@ABsteward) January 20, 2023
🌟The Four Moments of Antibiotic Decision Making🌟 #IDTwitter https://t.co/VCccsgQ7Jw pic.twitter.com/iGjguYbubO
— Antibiotic Steward Bassam Ghanem🆔🌟 (@ABsteward) January 23, 2023
Oral Is the New IV. Challenging Decades of Blood and Bone Infection Dogma: A Systematic Review https://t.co/2aSTZNzQW4
— Brad Spellberg (@BradSpellberg) January 22, 2023
Today @JanssenUS announced that the DSMB review of the MOSAICO phase 3 HIV vaccine study determined that the vaccine was no effective in preventing HIV. Incredibly disappointing that yet another HIV vaccine fails to show efficacy in a clinical trial. https://t.co/UZeUjrMTmf
— Carlos del Rio (@CarlosdelRio7) January 18, 2023
So do ampicillin and amoxicillin share a side chain?@glavaidguy @PharmerMeg @not_that_CDC @EricMacyMD https://t.co/k09uqWH3pYhttps://t.co/MF3KCvuqYOhttps://t.co/MkSbE1mBzg pic.twitter.com/uJok4ldgSe
— Bug Pharmacist 💊🧫 Tim Gauthier (@IDstewardship) January 19, 2023
Clostridioides Difficile Infection (European Society of Clinical Microbiology & Infectious Diseases)https://t.co/bcC2a0FXBr#MedEd #MedTwitter #IDTwitter #PharmaTwitter #Bioinformatics #infection #ICU #CriticalCare #internalmedicine #primarycare #FOAMcc #healthcare #hospitalist pic.twitter.com/pqhlwoD1r5
— ApoThera - Clinical Decision Support - Mobile App (@ApoThera) January 20, 2023
#AntimicrobialResistance requires a #OneHealth solution. In @NatureMedicine today we issue a call to action:
— Shira Doron MD (@ShiraDoronMD) January 20, 2023
Human and veterinary antimicrobial stewardship leaders must join forces, share best practices, educate trainees together. https://t.co/JdYusYU5tg
Revive Therapeutics Submits Updated Briefing Package in Support of Upcoming Type C Meeting Granted by #FDA for Amended Protocol Agreement of Phase 3 Clinical Study for #Bucillamine in the Treatment of #COVID19
— Revive Therapeutics (CSE: RVV, US: RVVTF) Official (@Revive_RVV) January 19, 2023
Learn more: https://t.co/qWxILgAl43 $RVV $RVVTF #Infectiousdiseases pic.twitter.com/oGTbq6krkp
The president of Japan's Association of Infectious Diseases says that "Covid is often the second or even third cause of their death" when elderly Japanese people die with the virus. https://t.co/yvri1DSFSy pic.twitter.com/g9ZLSlNqOF
— Anthony LaMesa (@ajlamesa) January 19, 2023
A promising approach to control #Staphylococcus aureus bacterial colonization in people (using a #probiotic instead of antibiotics) was safe & highly effective in a Phase 2 @NIH clinical trialhttps://t.co/hOSXxeKT8N #MRSA #probiotics
— MicrobesInfect (@MicrobesInfect) January 19, 2023
By far the clearest explanation of how we should think about the millions of lives saved by COVID-19 vaccines instead of social media misinformation
— Tim Lahey, MD, MMSc (@TimLaheyMD) January 17, 2023
Thanks @dr_kkjetelina https://t.co/xUvllilyv2
This meta-study showing strong and lasting protection from hybrid immunity is now published in Lancet Infectious Diseases.https://t.co/JgaMDCQn5D https://t.co/K2CD0vfMmU
— Prof. Michael S Fuhrer (@MichaelSFuhrer) January 19, 2023
New research: The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trialshttps://t.co/6EQ2VmUpHb
— The Lancet Infectious Diseases (@TheLancetInfDis) January 20, 2023
1) Secondary Bacterial Infection of Eczema (NICE)https://t.co/x99iv5yBzl#MedEd #MedTwitter #Eczema #IDTwitter #PharmaTwitter #infectiousdiseases #Bioinformatics #primarycare #internalmedicine #USMLE #USMLESTEP3 #usmlestep1 #telemedicine #telehealth #antibiotics #dermatologia pic.twitter.com/3G3SJ5POYc
— ApoThera - Clinical Decision Support - Mobile App (@ApoThera) January 22, 2023
What’s a service a pharmacist can do that most people have no idea about?
— Bug Pharmacist 💊🧫 Tim Gauthier (@IDstewardship) January 21, 2023
I’ll go first: penicillin allergy testing! 🙌https://t.co/mBRy1vzYKC #TwitteRx pic.twitter.com/4lJGI6ZGZB
#AntibioticResistance in pets is increasing due, in part, to overuse of #antibiotics.
— NIYIGENA Emmanuel (@NiyigenaE_) January 23, 2023
Reduced #antibiotic effectiveness is a threat to long-term health of our #pets
Let us #vaccinate to reduce #AMR
Cc: https://t.co/zJnNAh3AhT#RwOT#OneHealth #AntibioticStewardship#ARSMUN pic.twitter.com/Z2kqmgVkg0
Come join our exciting What’s New in Childhood TB webinar on 26/01. We'll discuss new ways of diagnosing, treating & preventing #pediatricTB & present 5 articles from the supplement of the Journal of Pediatric Infectious Diseases Society #EndTB
— Stop TB Partnership (@StopTB) January 23, 2023
👉Register https://t.co/VzYDeN52ye pic.twitter.com/idQbbAWWuH
Complex appendicitis? ✅
— Gabriele Pollara (@gpollara) January 18, 2023
Laparoscopic appendicectomy? ✅
How long to give post-op antibiotics? 🤔
🌟New 15-centre RCT indicates 2 days is just about as good as 5 days.@TheLancet #AMR #AntimicrobialResistance #antimicrobialstewardship https://t.co/BkJG8Ydl9g (1/2) pic.twitter.com/f2bZQCuoI8
🔥Just PUBLISHED 🔥
— Antibiotic Steward Bassam Ghanem🆔🌟 (@ABsteward) January 20, 2023
ATLAS-2M RCT Week 152 results @CIDJournal
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection #IDTwitter #Hivtwitter https://t.co/EHJeLwu4ZG
Prime Minister Kishida Fumio plans to instruct officials to study the steps needed to re-categorize COVID-19 into the same class of infectious diseases as seasonal flu. https://t.co/6mSwwDjOdt
— NHK WORLD News (@NHKWORLD_News) January 20, 2023
Aspergillus fumigatus is the most prevalent worldwide cause of fungal respiratory disease. A new study in #IAIJournal shows that the fungus drives tissue damage via iterative assaults on mucosal integrity and immune homeostasis. Learn more: https://t.co/UTdWLLUidf pic.twitter.com/sPcu7YsXvr
— ASM (@ASMicrobiology) January 19, 2023
One study that is conveniently missed in our discussions on our past respiratory season is this one, from New Zealand, with essentially no prior COVID, showing a return of RSV season with huge cases and 3x the ICU admissions than any other season
— Zain Chagla (@zchagla) January 21, 2023
1/https://t.co/U9WuFkSw7q pic.twitter.com/JAb5xyySni
✨Lecture Series on #InfectiousDiseases 2.0
— MERA-India ICMR (@MERAIndiaICMR) January 23, 2023
Join us #tomorrow for opening #lecture by👩🔬Dr Rangarajan, Director @CSIR_CDRI
Title: "Antibacterial #DrugDiscovery 🦠🧪💊: opportunities and challenges"
🗓️24th Jan |🕚11:00 am
🔗: https://t.co/Lnflm2eFjM#Microbiology#WomenInSTEM pic.twitter.com/v1Zc4QKVyb
Probiotic May Be a Promising Approach to Treating MRSA
— Genetic Engineering & Biotechnology News (@GENbio) January 22, 2023
Using a probiotic to control Staphylococcus aureus instead of antibiotics—was safe and highly effective in a Phase II clinical trial. Learn more: https://t.co/SbBCjx8e8k pic.twitter.com/k1TTzSdqgw
Principles for Ending Human Immunodeficiency Virus as an Epidemic in the United States: A Policy Paper of the Infectious Diseases Society of America and the HIV Medical Association
— Clinical Infectious Diseases (@CIDJournal) January 17, 2023
🆓 Freely Available
🔗 https://t.co/ac7A469tb3@HIVMA @IDSAInfo pic.twitter.com/KcRC2XVm2Y
Come be my colleague! Assistant/Associate Professor: Infectious Diseases & Center for Innovative Antimicrobial Therapy @IDPittStop @Pitt_CEBaM https://t.co/z3C32yVNaK
— Vaughn Cooper @vscooper@mstdn.science (@vscooper) January 18, 2023
CEPI (Coalition for Epidemic Preparedness Innovations) CEO highlights 100-day vaccine development goal.
— Rebel News (@RebelNewsOnline) January 20, 2023
"Infectious diseases and pandemics are truly a 21st-century threat, and one that we need to address systemically."
MORE: https://t.co/cc7736nMbT pic.twitter.com/OHFjFWM3GI
Ever wondered how many zoonotic viruses affect both humans & livestock?
— FAO Livestock (@FAOLivestock) January 18, 2023
Almost 50% of the 267 zoonotic viruses affecting humans are also found in livestock.
Download “Africa Sustainable Livestock 2050: Livestock and viral emerging infectious diseases”: https://t.co/z4J7MlTGxW pic.twitter.com/n9lmi8eJKe
#MicrobiologyMonday: Pseudomonas aeruginosa is resistant to grazing by the protist, Tetrahymena pyriformis. In mixed biofilms, it protects grazing-susceptible bacteria via secretion of toxic molecules that keep the protist at bay. #AppEnvMicro: https://t.co/yFA3zo2bIe pic.twitter.com/cXBpx7fXxy
— ASM (@ASMicrobiology) January 23, 2023
💊 I am delighted to share in this article about #Antibiotic Do’s and Don’ts: A Comprehensive Guide for #AntibioticSafetyhttps://t.co/e18X5P5EgF#AntibioticSafety #AntibioticUsageGuideline#AntimicrobialResistance #AntimicrobialStewardship pic.twitter.com/myprFXOXqd
— Rasha Abdelsalam Elshenawy💙 (@salam_rasha) January 23, 2023
Putting research into practice.
— Marc Mendelson (@SouthAfricanASP) January 23, 2023
Thank you @LancetGH for acting on @e_charani @seyeabimbola @SameedShariq @alexandra_mcp @oluch1_nm & colleagues excellent work. @PLOSGPH @GlobalHealthBMJ @Nature @Science @scientificamer
Words matter, and so do imageshttps://t.co/SstaJKRZPj pic.twitter.com/lNiQAH1aCW
Created by Cameron Forbes. Last updated January 31, 2023 at 05:16 EST.